## Assessment, recommendation and national procurement of new hospital medicines

Joint national procurement decision ("procurement ring") on procurement (Administrative decision by authority)

Hospital districts are represented in National Advisory Committee on Pharmaceuticals

The national procurement ring launches the negotiations on products with a conditional recommendation
- HUS Pharmacy is in contact with the company

The recommendation sets the basis for decision-making or negotiations

The COHERE process is grounded on the Fimea assessment and constitutes the basis for decision-making

HTA-assessment sets the basis for recommendation Fimea's assessment process opens the path towards decision-making

 National procurement is made in line with the agreement reached in the negotiation process

- The National Advisory Committee on Pharmaceuticals commits itself to the recommendation
- The Committee also commits to Yes / No recommendations
  - Negotiations are launched based on COHERE's conditional recommendation (COHERE = Council for Choices in Health Care in Finland)
  - HUS Pharmacy is the negotiator with the mandate from procurement rings
    - COHERE prepares the recommendation of the new hospital medicines assessed by Fimea
    - The conditional recommendation launches the negotiations
    - Yes / No recommendation to the Committee
       → no negotiations
    - Companies can ask for new recommendation from COHFRE
      - HTA of the new medicine is performed by Fimea



## National procurements of new hospital medicines - novel pharmaceutical molecules with a conditional COHERE recommendation

- · HUS Pharmacy has the mandate to negotiate
- HUS Pharmacy is in contact with the company
- The company can ask to postpone the negotiations



· Meets regularly, e.g., once a month and in the beginning whenever necessary

· The meeting times will later be aligned with the negotiations and, e.g., the COHERE meetings

 $\wedge$ 

t



regional decisions **National Advisory** Committee on Pharmaceuticals.

 $\wedge$ 

Communication

to hospital

districts

· Nation-wide Market

Entry Agreements do

not require further

Introduction starts

· Follow-up of progress along with the contractual terms starts



Follow-up of contractual terms



The negotiations

only involve those

with a conditional

recommendation,

 The COHERE recommendation regards a novel molecule with a HTA made by Fimea



**HUS Pharmacy** launches the negotiations

- The conditions for Market Entry Agreements (e.g. price, effectiveness or indicators followed)
- · Length of contractual period

Other contractual terms




National-wide commitment to procurement decisions, introduction and contractual terms

Information on decision posted at the Committee's site for information

Hospital districts can procure the

new medicine





 Companies can ask for new negotiations only for justified cause

